ClinicalTrialsFinder

PIK3CA Mutations Clinical Trials in St Louis, Missouri

1 recruitingSt Louis, Missouri

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

Endometrial CancerHER2-low Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more
Cogent Biosciences, Inc.90 enrolled4 locationsNCT07383506